Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (121-130 of 440) with videos related to

Pageof 44
Sort By:
Immunologic Research|June 8, 2004
Reconstructing immunity after allogeneic transplantationCynthia R Giver, Jian-Ming Li, Mohammad S Hossain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptorsEbenezer David, Rajni Sinha, Jing Chen, et al.
British Journal of Haematology|July 23, 2011
Monoclonal antibodies in the treatment of multiple myelomaPaul G Richardson, Sagar Lonial, Andrzej J Jakubowiak, et al.
Blood|August 25, 2005
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKTEbenezer David, Shi-Yong Sun, Edmund K Waller, et al.
Expert Review of Hematology|January 30, 2014
Current strategies for treatment of relapsed/refractory multiple myelomaJacob P Laubach, Peter M Voorhees, Hani Hassoun, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 1, 2014
Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case seriesAjay K Nooka, R Donald Harvey, Amelia Langston, et al.
Cancer Research|May 19, 2007
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cellsXiangguo Liu, Ping Yue, Shuzhen Chen, et al.
Pharmacological Research|November 26, 2016
Deacetylase inhibitors as a novel modality in the treatment of multiple myelomaPaul G Richardson, Philippe Moreau, Jacob P Laubach, et al.
Expert Review of Hematology|September 9, 2017
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agentPaul Richardson, Anuja Roy, Suddhasatta Acharyya, et al.
Cancer|July 13, 2016
Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participationAjay K Nooka, Madhusmita Behera, Sagar Lonial, et al.
Pageof 44

Showing results (121-130 of 440) with videos related to

Sort By:
Pageof 44
Immunologic Research|June 8, 2004
Reconstructing immunity after allogeneic transplantationCynthia R Giver, Jian-Ming Li, Mohammad S Hossain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptorsEbenezer David, Rajni Sinha, Jing Chen, et al.
British Journal of Haematology|July 23, 2011
Monoclonal antibodies in the treatment of multiple myelomaPaul G Richardson, Sagar Lonial, Andrzej J Jakubowiak, et al.
Blood|August 25, 2005
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKTEbenezer David, Shi-Yong Sun, Edmund K Waller, et al.
Expert Review of Hematology|January 30, 2014
Current strategies for treatment of relapsed/refractory multiple myelomaJacob P Laubach, Peter M Voorhees, Hani Hassoun, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 1, 2014
Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case seriesAjay K Nooka, R Donald Harvey, Amelia Langston, et al.
Cancer Research|May 19, 2007
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cellsXiangguo Liu, Ping Yue, Shuzhen Chen, et al.
Pharmacological Research|November 26, 2016
Deacetylase inhibitors as a novel modality in the treatment of multiple myelomaPaul G Richardson, Philippe Moreau, Jacob P Laubach, et al.
Expert Review of Hematology|September 9, 2017
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agentPaul Richardson, Anuja Roy, Suddhasatta Acharyya, et al.
Cancer|July 13, 2016
Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participationAjay K Nooka, Madhusmita Behera, Sagar Lonial, et al.
Pageof 44